Enasidenib as Maintenance Following Allogeneic HCT for IDH2-Mutated Myeloid Malignancies
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Blood Advances
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Enasidenib as Maintenance following Allogeneic Hematopoietic Cell Transplantation for IDH2-Mutated Myeloid Malignancies
Blood Adv 2022 Sep 23;[EPub Ahead of Print], AT Fathi, HT Kim, RJ Soiffer, MJ Levis, S Li, AS Kim, AS Mims, Z DeFilipp, A El-Jawahri, SL McAfee, AM Brunner, R Narayan, LW Knight, D Kelley, AS Bottoms, LS Perry, JL Wahl, J Brock, E Breton, VT Ho, YB ChenFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.